top of page

LATEST NEWS

June 2024

  • All the links have been checked and are working properly.

  • The number of current clinical trials was updated accordingly.

  • ARX-517: clinical trials have been consolidated from Phase 2 to Phase 1.

  • BT5528 was consolidated from Phase 1 to Phase 2. 

  • Griffthisin: no longer has clinical trials.

 

April 2024

  • ARX-788: clinical trials have been consolidated from Phase 1 to Phase 3.

  • STRO-002: clinical trials have been consolidated from Phase 1 to Phase 2.

  • FOR-46: clinical trials have been consolidated from Phase 1 to Phase 2

  • ARX-517: clinical trials have been consolidated from Phase 1 to Phase 2

  • STI-6129: clinical trials have been consolidated from Phase 1 to Phase 2

  • SGN-B6A: clinical trials have been consolidated from Phase 1 to Phase 3

  • RC-88: clinical trials have been consolidated from Phase 1 to Phase 2

  • ARX-517: clinical trials have been consolidated from Phase 1 to Phase 2

  • Upifitamab rilsodotin (XMT-1536): clinical trials have been consolidated from Phase 1 to Phase 2

  • MRG003: clinical trials have been consolidated from Phase 1 to Phase 3.

  • A-166: clinical trials have been consolidated from Phase 1 to Phase 2

  • BT8009: clinical trials have been consolidated from Phase 2 to Phase 3.

  • ALT-P7: Removed from Phase I. No longer has active clinical trials.

  • Farletuzumab ecteribulin (MORAb-202): clinical trials have been consolidated from Phase 1 to Phase 2

  • EBC-129: a new row for this new Phase 1 study was added

February 2024

  • All the links have been checked and are working properly.

  • The number of current clinical trials was updated accordingly.

  • MRG003: The link for U.S. Clinical trials and Chinese clinical trials were updated.

  • ALTP-7: although one clinical trial is listed on clinicaltrials.gov  as completed, it remains on the manufacturer website.

  • SGN-B6A: Pfizer has completed the acquisition of Seagen, so the link is to Pfizer’s website.

  • SGN-CD228A: has been removed as the only clinical trial listed is terminated and it no longer is present in the on the Seagen/Pfizer clinical pipeline.

  • A-166: Link for U.S. clinical trials was updated.

  • Upifitamab rilsodotin (XMT-1536): Clinical trials in U.S shows 1 trial that is “active, not recruiting”. Most recently the FDA paused Upifitamab rilsodotin trials: FDA Pauses Upifitamab Rilsodotin Trials in Platinum-Sensitive Ovarian Cancer (cancernetwork.com)

  • ARX-517: a new row was added.

  • Leucettinib-21: a new row was added.

December 2023

  • All the links have been checked and are working properly. 

  • The number of current clinical trials was updated accordingly. 

  • MRG003: Link for Chinese clinical trials was updated. 

  • A-166: Link for U.S. clinical trials was updated. 

  • Upifitamab rilsodotin (XMT-1536): Clinical trials in U.S shows 1 trial that is “active, not recruiting”. 

  • Most recently the FDA paused Upifitamab rilsodotin trials: FDA Pauses Upifitamab Rilsodotin Trials in Platinum-Sensitive Ovarian Cancer (cancernetwork.com)

  • ARX-517: a new row was added.

October 2023

  • All the links have been checked and are properly working. 

  • BT8009 target was updated to Nectin-4 (PVRL4).

  • Name of MORAb202 was updated to Farleztuzumab ecteribulin and the chemical class updated to ADC (Ecteribulin).

  • New row added for compounds PM54 and PM534

  • Removed indication for HIV for griffithsin, due to the fact that the clinical trial for this indication was terminated. 

  • The number of current clinical trials was updated accordingly. 

 

August 2023

  • All the links have been checked and are properly working. 

June 2023:

  • All the links have been checked and are working properly.

  • The number of current clinical trials was updated accordingly.

  • New links were added for the “Compound Name” for: STRO-002, Cofetuzumab pelidotin, and STI-6129.

April 2023

  • Link for Cofetuzumab pelidotin’s “Company/Institution” has been updated with AbbVie's current pipeline webpage. All other links have been checked and are properly working.

  • The number of current clinical trials was updated accordingly.

Points discussed during meeting:

  • PF-06804103: This compound has no more active clinical trials; it is not found in the Pipeline on Pfizer’s website anymore either. It was decided to remove this compound in the Phase 1 page.

  • SGN-CD228A: This compound’s Phase 1 study is “terminated”; however, it is still on the Pipeline under phase 1 on Seagen’s website. It was decided we should keep this compound in the Phase 1 page for some months.

February 2023

  • All the links have been checked and were working properly. 

  • The number of current clinical trials was updated accordingly.

  • Link has been updated to show the company's pipeline page for A-166. 

  • Compound name for MorAb-202 has been updated to Farletuzumab Ecteribulin (MorAb-202). 

  • New compound, EBC-129, has been added. 
     

December 2022 

All the links have been checked and were working properly. The number of clinical trials in Phase 1 is currently reflected on the website. Recent updates to phase 1 clinical trials include compounds completing phase 1, progressing to phase 2, and phase 3. 

  • ARX-788: has six trials in progress: 1 phase 1 trial, 5 phase 2 trials, and 1 phase 3 trial.   

  • XMT-153:  named upifitamab rilsodotin, has 2 phase 1 trials, 1 phase 2 trial and 1 phase 3 trial.  

  • MORAb-202: has 3 phase 2 trials, and 1 phase 1 trial.   

  • MRG003: has 5 phase 2 trials, and 1 phase 1 trial.  

  • RC-88: has 1 phase 2 trial, and 2 phase 1 trials.  

  • STI-6129:  3 Phase 2 trials, and 5 phase 1 trials.   

September 2022

Approved Marine Drugs
© 2021-2024 Marine Pharmacology
© 2021-2024 Marine Pharmacology
bottom of page